Symeres Names Gabriella Gentile as COO

Symeres, a global Contract Research, Development and Manufacturing Organization (CRDMO), has appointed Gabriella Gentile as Chief Operating Officer (COO). This strategic addition to the executive team supports Symeres’ transatlantic growth ambitions, building upon its foundations in existing and novel modalities. 

In her new role, Gentile will lead the transformation of global operations at Symeres, focusing on expanding capabilities across the pharmaceutical value chain from inception to investigational new drug (IND). She will apply her leadership to align business operations with measurable performance outcomes, reinforcing Symeres’ commitment to quality and customer satisfaction. 

Guillaume Jetten, Symeres CEO, said, “I’m delighted that Gabriella has accepted this position. Gabriella brings a set of highly relevant skills and experience from both her background in medicinal chemistry, but also her decades of large Pharma and biotech experience that will support the future growth plans of Symeres.” 

Experience 

Gentile brings more than 25 years of international experience in the pharmaceutical, medical device, and services industries. She has held senior roles at Catalent, Roche and Aptuit, where she led major transformation programs focused on operational performance, lean methodologies, and change management. 

Most recently, Gentile served as global improvement director at Catalent, where she developed and implemented standardized operational frameworks across multiple sites. Prior to that, she consulted independently on global change and operational excellence programs, helping organizations improve performance and implement strategic business initiatives. 

“I’m delighted to join Symeres at this exciting time in their growth,” said Gentile, “Symeres operates under a cultural philosophy of openness and transparency, and I look forward to being part of developing new next generation therapies.”